{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:01:05Z","timestamp":1789016465258,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12094-020-02472-x","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T10:04:12Z","timestamp":1597313052000},"page":"799-811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-8916","authenticated-orcid":false,"given":"J.","family":"Mu\u00f1oz-Langa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. O.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B G.","family":"de Tejada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. B.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Adri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. P.","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. O.","family":"Portero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. S.","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. T.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. O.","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Altozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1. R.","family":"Lescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mu\u00f1oz-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"issue":"10","key":"2472_CR1","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cncr.23062","volume":"110","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339\u201346.","journal-title":"Cancer"},{"issue":"4","key":"2472_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1055\/s-0037-1613051","volume":"87","author":"S Sallah","year":"2002","unstructured":"Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87(4):575\u20139.","journal-title":"Thromb Haemost"},{"issue":"7","key":"2472_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cncr.25714","volume":"117","author":"G Lyman","year":"2011","unstructured":"Lyman G. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011;117(7):1334\u201349.","journal-title":"Cancer"},{"key":"2472_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","volume":"162","author":"JA Heit","year":"2002","unstructured":"Heit JA, O\u2019Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245\u20138.","journal-title":"Arch Intern Med"},{"key":"2472_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0049-3848(01)00235-3","volume":"102","author":"HM Otten","year":"2001","unstructured":"Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res. 2001;102:187\u201394.","journal-title":"Thromb Res"},{"key":"2472_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJM199210153271604","volume":"327","author":"P Prandoni","year":"1992","unstructured":"Prandoni P, Lensing AWA, B\u00fcller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128\u201333.","journal-title":"N Engl J Med"},{"key":"2472_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","volume":"24","author":"AA Khorana","year":"2006","unstructured":"Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24:484\u201390.","journal-title":"J Clin Oncol"},{"key":"2472_CR8","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484\u20138.","journal-title":"Blood"},{"key":"2472_CR9","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S\u201394S.","journal-title":"Chest"},{"key":"2472_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/CIR.0b013e318214914f","volume":"123","author":"MR Jaff","year":"2011","unstructured":"Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788\u2013830.","journal-title":"Circulation"},{"key":"2472_CR11","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","volume":"18","author":"BA Hutten","year":"2000","unstructured":"Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding com- plications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078\u201383.","journal-title":"J Clin Oncol"},{"key":"2472_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1055\/s-0037-1614120","volume":"84","author":"G Palareti","year":"2000","unstructured":"Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D\u2019Angelo A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84:805\u201310.","journal-title":"Thromb Haemost"},{"key":"2472_CR13","unstructured":"Ageno W, McCallum P, Haas S, Weitz JI, Angchaisuksiri P, Bounameaux H, et al. Clinical characteristics and management of 10,329 patients with a confirmed diagnosis of venous thromboembolism: the GARFIELD-VTE registry. Research and practice in Thrombosis and Haemostasis. 2017;1(Suppl1):1-1451. Abstract ASY 35.4."},{"key":"2472_CR14","unstructured":"Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M, Custodio A, Raquel Hernandez R, Alejandra Lacalle, et al. A Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients With Cancer. Thromb Haemost. 2019, 119 (11), 1849-1859."},{"key":"2472_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"2472_CR16","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, for the Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119\u201326.","journal-title":"J Thromb Haemost"},{"issue":"9162","key":"2472_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/s0140-6736(98)07534-5","volume":"53","author":"SZ Goldhaber","year":"1999","unstructured":"Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;53(9162):1386\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(98)07534-5.","journal-title":"Lancet"},{"issue":"6","key":"2472_CR18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jacc.2010.05.071","volume":"57","author":"CV Pollack","year":"2011","unstructured":"Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O\u2019Neil BJ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol. 2011;57(6):700\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.071.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2472_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.thromres.2012.08.292","volume":"130","author":"F Casazza","year":"2012","unstructured":"Casazza F, Becattini C, Bongarzoni A, Cuccia C, Roncon L, Favretto G, et al. Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). Thromb Res. 2012;130(6):847\u201352. https:\/\/doi.org\/10.1016\/j.thromres.2012.08.292.","journal-title":"Thromb Res"},{"issue":"1","key":"2472_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0033-1363473","volume":"40","author":"W Ageno","year":"2014","unstructured":"Ageno W, Riva N, Schulman S, Bang SM, Sartori MT, Grandone E, et al. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost. 2014;40(1):99\u2013105. https:\/\/doi.org\/10.1055\/s-0033-1363473.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2472_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.thromres.2007.06.009","volume":"121","author":"G Agnelli","year":"2008","unstructured":"Agnelli G, Verso M, Ageno W, Imberti D, Moia M, Palareti G, et al. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res. 2008;121(5):605\u201310. https:\/\/doi.org\/10.1016\/j.thromres.2007.06.009.","journal-title":"Thromb Res"},{"issue":"5","key":"2472_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/annonc\/mdp406","volume":"21","author":"N Kucher","year":"2010","unstructured":"Kucher N, Spirk D, Baumgartner I, Mazzolai L, Korte W, Nobel D, et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol. 2010;21(5):931\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdp406.","journal-title":"Ann Oncol"},{"key":"2472_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12959-015-0071-z","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, et al. The management of acute venous thromboembolism in clinical practice\u2013study rationale and protocol of the European PREFER in VTE Registry. Thromb J. 2015;13:41. https:\/\/doi.org\/10.1186\/s12959-015-0071-z.","journal-title":"Thromb J"},{"key":"2472_CR24","doi-asserted-by":"publisher","first-page":"e008157","DOI":"10.1136\/bmjopen-2015-008157","volume":"5","author":"B Frank","year":"2015","unstructured":"Frank B, Ariza L, Lamparter H, et al. Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project. BMJ Open. 2015;5:e008157.","journal-title":"BMJ Open"},{"issue":"1","key":"2472_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1160\/TH17-07-0511","volume":"118","author":"B Bikdeli","year":"2018","unstructured":"Bikdeli B, Jimenez D, Hawkins M, Ort\u00edz S, Prandoni P, Brenner B, et al. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost. 2018;118(1):214\u201324. https:\/\/doi.org\/10.1160\/TH17-07-0511.","journal-title":"Thromb Haemost"},{"key":"2472_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cllc.2016.10.007","volume":"18","author":"A Zer","year":"2017","unstructured":"Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, et al. ALK-rearranged non-small-cell lung cancer Is associated with a high rate of venous thromboembolism. Clin Lung Cancer. 2017;18:156\u201361.","journal-title":"Clin Lung Cancer"},{"key":"2472_CR27","doi-asserted-by":"crossref","unstructured":"Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, D\u00f3mine M, Nadal E et al. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J. 2018;51. pii: 1702431.","DOI":"10.1183\/13993003.02431-2017"},{"key":"2472_CR28","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","volume":"29","author":"RA Moore","year":"2011","unstructured":"Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy. A large retrospective analysis. J Clin Oncol. 2011;29:3466\u201373.","journal-title":"J Clin Oncol"},{"key":"2472_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-9-179","volume":"9","author":"S Barni","year":"2011","unstructured":"Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandal\u00e0 M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.","journal-title":"J Transl Med"},{"key":"2472_CR30","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1160\/TH16-04-0335","volume":"116","author":"JI Weitz","year":"2016","unstructured":"Weitz JI, Haas S, Ageno W, Angchaisuksiri P, Bounameaux H, Nielsen JD, et al. Global Anticoagulant Registry in the Field\u2013Venous Thromboembolism (GARFIELD-VTE) Rationale and design. Thromb Haemost. 2016;116:1172\u20139. https:\/\/doi.org\/10.1160\/TH16-04-0335.","journal-title":"Thromb Haemost"},{"issue":"6","key":"2472_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/jth.12955","volume":"13","author":"S Schulman","year":"2015","unstructured":"Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015;13(6):1010\u20138. https:\/\/doi.org\/10.1111\/jth.12955.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2472_CR32","doi-asserted-by":"publisher","first-page":"e018910","DOI":"10.1136\/bmjopen-2017-018910","volume":"8","author":"Yasuo Ohashi","year":"2018","unstructured":"Ohashi Yasuo, Ikeda Masataka, Kunitoh Hideo, Sasako Mitsuru, Okusaka Takuji, Mukai Hirofumi, et al. Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry). BMJ Open. 2018;8(5):e018910. https:\/\/doi.org\/10.1136\/bmjopen-2017-018910.","journal-title":"BMJ Open"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02472-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T20:43:59Z","timestamp":1667767439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02472-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2472"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02472-x","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JML: consultant or Advisory Role: LEO Pharma. Sanofi. Rovi. Speaking: Sanofi, LeoPharma, Rovi. Travel, Accommodations: LeoPharma, Sanofi. PJF: consultant or advisory role: Roche, Bristol, Mylan, Rovi, Sanofi, LeoPharma; travel grants: Ipsen. ACB: consultant or advisory role: Roche, Rovi, Sanofi, LeoPharma, Pfizer, Esteve; travel grants: Ipsen, Roche, Novartis. EMC: consultant or Advisory Role: Pfizer, Amgen. Speaking: Roche, Pfizer, Amgen, Sanofi, LeoPharma, Rovi, Celgene. Travel, Accommodations: Roche, Pfizer, Celgene, Sanofi. PPS: consultant or Advisory Role: Novartis, BMS, Merck. Travel, Accommodations: MSD, Merck. MSC: consultant or Advisory Role: KyowaKirin. Research Funding: LeoPharma. Financial support for educational programs: Angelini, Sanofi, Rovi, LeoPharma, Servier. Remunerations for authorship: KyowaKirin, Mylan. Travel, Accommodations: Sanofi, MSD, Esteve, Amgen, Servier, Angelini, Leo Pharma. DG: None. LOM: consultant or Advisory Role: Sanofi. Speaking: Amgen, Sanofi, Leo-Pharma. Travel, Accommodations: Roche, Amgen, Sanofi, LeoPharma. MBGT: Speaker: Rovi, Leo Pharma, Sanofi, Sponsored Academic Activities: Rovi, Leo Pharma. ES: None. GBL: None. SGA: consultant\/advisory honorarium Eisai, Celgene, Roche, Pierre Fabre, Novartis, Sanofi Aventis and Astra Zeneca. MCC: consultant\/advisory Role: Leo pharma. Speaking: Rovi. VPO: Advisory board: Daichi. Speaking: Sanofi, Leo-Pharma. BOP: none. MSM: none. JASC: advisory board; Sanofi, Servier. LTS: none. MAR: none. POR: none. JPA: none ARL: Consultant or Advisory Role: Roche, Pfizer, Novartis, Lilly, Mylan. Speaking: Roche, Pfizer, Novartis, Lilly, Kern, A-Z, Mylan, Eisai. Travel, Accommodations (ASCO, SABCS): Roche, Novartis. Research Funding To my Institution: Roche, Novartis, Pfizer, Lilly, Astra-Zeneca, Amgen, MSD. AM: consulting, lectures and advisory board: Sanofi, Celgene, Astra-Zeneca, Roche, Leo Pharma, Servier, Pfizer, Bristol-Myers Squibb, Daiichi Sankyo, Bayer, Halozyme, Amgen, Rovi, Merck Sharp & Dohme and Lilly. Research funding: Sanofi, LEO Pharma, Celgene. Travel, Accommodations: Roche, Merck Serono, Amgen, Celgene. All outside of the scope of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed are in accordance with the ethical standards of the committee in charge of human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"was obtained from all patients before they were included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}